Should thyroxine treatment be discontinued for four weeks before 131I thyroid ablation

作者: Reyes Luna , Manuel Penín , Inés Seoane , Elías Álvarez , Regina Palmeiro

DOI: 10.1016/J.ENDOEN.2012.04.012

关键词:

摘要: Abstract Background It is a usual practice to discontinue thyroxine treatment for four weeks before 131I ablation. Symptoms of hypothyroidism usually occur during this time. Use rhTSH helpful alternative in some cases, but problems availability agent 2012 will limit its use. Patients and methods Plasma TSH FT4 levels were measured on days 7, 14, 21, 28 after total thyroidectomy (12 patients) or discontinuation (20 patients). A Mann–Whitney U-test was used compare quantitative variables, Chi-square test nominal variables. Results On day 30 μIU/mL higher 71% patients (66% the group 75% discontinued treatment). almost all from both groups (91% 100% treatment) had higher. most below normal range. Conclusions Discontinuation not required. Fourteen an adequate time patients, 21 are sufficient virtually patients.

参考文章(27)
Harry R. Maxon, Howard S. Smith, Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinology and Metabolism Clinics of North America. ,vol. 19, pp. 685- 718 ,(1990) , 10.1016/S0889-8529(18)30317-7
Chao Ma, Jiawei Xie, Wanxia Liu, Guoming Wang, Shuyao Zuo, Xufu Wang, Fengyu Wu, Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer. Cochrane Database of Systematic Reviews. ,(2010) , 10.1002/14651858.CD008302.PUB2
HAJIME TAMAI, HIROYUKI SUEMASTU, NOBUO KUROKAWA, MASAHIRO ESAKI, TUJIRO IKEMI, FUMIO MATSUZUKA, KANJI KUMA, SHIGENOBU NAGATAKI, Alterations in circulating thyroid hormones and thyrotropin after complete thyroidectomy. The Journal of Clinical Endocrinology and Metabolism. ,vol. 48, pp. 54- 58 ,(1979) , 10.1210/JCEM-48-1-54
Hanna O. Mäenpää, Jorma Heikkonen, Leila Vaalavirta, Mikko Tenhunen, Heikki Joensuu, Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLOS ONE. ,vol. 3, ,(2008) , 10.1371/JOURNAL.PONE.0001885
W.J. Simpson, T. Panzarella, J.S. Carruthers, M.K. Gospodarowicz, S.B. Sutcliffe, PAPILLARY AND FOLLICULAR THYROID CANCER: IMPACT OF TREATMENT IN 1578 PATIENTS International Journal of Radiation Oncology Biology Physics. ,vol. 14, pp. 1063- 1075 ,(1988) , 10.1016/0360-3016(88)90381-1
James C. Sisson, Thomas J. Giordano, David A. Jamadar, Ella A. Kazerooni, Brahm Shapiro, Milton D. Gross, Shirley A. Zempel, Susan A. Spaulding, 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma Cancer. ,vol. 78, pp. 2184- 2192 ,(1996) , 10.1002/(SICI)1097-0142(19961115)78:10<2184::AID-CNCR21>3.0.CO;2-U
C. J. Edmonds, Susan Hayes, J. C. Kermode, B. D. Thompson, Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. British Journal of Radiology. ,vol. 50, pp. 799- 807 ,(1977) , 10.1259/0007-1285-50-599-799
Ernest L. Mazzaferri, Sissy M. Jhiang, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer The American Journal of Medicine. ,vol. 97, pp. 418- 428 ,(1994) , 10.1016/0002-9343(94)90321-2
SCHLUMBERGER MARTIN, TUBIANA MAURICE, FLORENT DE VATHAIRE, HILL CATHERINE, PAULE GARDET, JEAN-PAUL TRAVAGLI, PHILIPPE FRAGU, JEAN LUMBROSO, BERNARD CAILLOU, CLAUDE PARMENTIER, Long-Term Results of Treatment of 283 Patients with Lung and Bone Metastases from Differentiated Thyroid Carcinoma The Journal of Clinical Endocrinology and Metabolism. ,vol. 63, pp. 960- 967 ,(1986) , 10.1210/JCEM-63-4-960